Trial · NCT06665178
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
NCT06665178, Phase 2, Recruiting, British Columbia Cancer Agency
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer. Trials, record NCT06665178. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06665178
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
- NCT number
- NCT06665178
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- British Columbia Cancer Agency
- Conditions
- Breast Cancer
- Interventions
- Sacituzumab Govitecan
- First posted
- 2024-10-30
- Last updated
- 2025-06-25
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Altered Tumor Genes by PFS Duration on SG Post T-DXd | Up to an average of 6 months | Number and identification of altered/mutated genes in the tumors in the subgroup of patients with a longer PFS on SG post T-DXd compared to the tumors in the subgroup of patients with a shorter PFS on SG post T-DXd. |
| Secondary | Progression free survival (PFS) | Up to an average of 6 months | Progression free survival (PFS) of SG post T-DXd in ER+/HER2 low MBC as measured by RECIST criteria |
| Secondary | Response rate (RR) | Up to an average of 6 months | Response rate (RR) of SG post T-DXd as measured by RECIST 1.1 criteria |
| Secondary | Grade 2-4 toxicities | Up to an average of 3 months | Number of Participants with the CTCAE version 5 grade 2-4 toxicities reported in SG post T-DXd in ER+/HER2 low MBC |
| Secondary | Overall survival | Up to an average of 12 months | Overall survival of SG post T-DXd |
| Secondary | Trop-2 expression and HER-2 expression | Up to an average of 12 months | Trop-2 expression and HER-2 expression by IHC in the metastatic biopsy and correlation with PFS and RR |
| Secondary | Dose intensity | Up to an average of 3 months | Dose intensity (with and without growth factor support) of SG delivered post T-DXd in ER+/HER2 low MBC |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06665178
GET https://conductscience.org/api/trials/v1/NCT06665178/registered